Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Tarsus Pharmaceuticals, Inc. (TARS : NSDQ)

• Company Description    Tarsus Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of therapeutic candidates to address ophthalmic conditions. The company's product candidate consist TP-03 which is in clinical stage. Tarsus Pharmaceuticals Inc. is based in IRVINE, Calif. Number of Employees: 370

• Price / Volume Information    Yesterday's Closing Price: $73.00 Daily Weekly Monthly 20 Day Moving Average: 758,869 shares Shares Outstanding: 43.88 (millions) Market Capitalization: $3,203.46 (millions) Beta: 0.44 52 Week High: $91.53 52 Week Low: $53.89 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -19.59% -19.63% 12 Week 25.56% 23.16% Year To Date -10.85% -20.97%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 17700 LAGUNA CANYON ROAD FLOOR 4 - IRVINE,CA 92618 USA ph: 949-418-1801 fax: - ir@tarsusrx.com http://www.tarsusrx.com

• General Corporate Information    Officers Bobak Azamian - President; Chief Executive Officer and Chairman Jeffrey Farrow - Chief Financial Officer and Chief Strategy Officer Bhaskar Chaudhuri - Director Andrew Goldberg - Director Katherine Goodrich - Director Peer Information Tarsus Pharmaceuticals, Inc. (CORR.) Tarsus Pharmaceuticals, Inc. (RSPI) Tarsus Pharmaceuticals, Inc. (CGXP) Tarsus Pharmaceuticals, Inc. (BGEN) Tarsus Pharmaceuticals, Inc. (GTBP) Tarsus Pharmaceuticals, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 87650L103 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/03/26 Share - Related Items Shares Outstanding: 43.88 Most Recent Split Date: (:1) Beta: 0.44 Market Capitalization: $3,203.46 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-3.45 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-4.25 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/03/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 9.24 Price/Cash Flow: - Price / Sales: 5.28 EPS Growth vs. Year Ago Period: 10.42% vs. Previous Quarter: -168.75% Sales Growth vs. Year Ago Period: 69.41% vs. Previous Quarter: 7.32% ROE 09/30/26 - - 06/30/26 - -13.53 03/31/26 - -14.19 ROA 09/30/26 - - 06/30/26 - -8.12 03/31/26 - -8.89 Current Ratio 09/30/26 - - 06/30/26 - 3.20 03/31/26 - 3.74 Quick Ratio 09/30/26 - - 06/30/26 - 3.17 03/31/26 - 3.71 Operating Margin 09/30/26 - - 06/30/26 - -7.67 03/31/26 - -9.02 Net Margin 09/30/26 - - 06/30/26 - -7.67 03/31/26 - -9.02 Pre-Tax Margin 09/30/26 - - 06/30/26 - -6.49 03/31/26 - -8.20 Book Value 09/30/26 - - 06/30/26 - 7.90 03/31/26 - 8.11 Inventory Turnover 09/30/26 - - 06/30/26 - 9.50 03/31/26 - 8.38 Debt-to-Equity 09/30/26 - - 06/30/26 - 0.21 03/31/26 - 0.21 Debt-to-Capital 09/30/26 - - 06/30/26 - 17.34 03/31/26 - 17.22

Powered by Zacks Investment Research ©